{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T11:19:19Z","timestamp":1756379959196,"version":"3.44.0"},"reference-count":23,"publisher":"BMJ","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["DTB"],"published-print":{"date-parts":[[2009,7]]},"abstract":"<jats:p>Melatonin, a hormone produced by the pineal gland, has a key role in regulating circadian rhythms, most importantly, the sleep-wake cycle.1 Melatonin's action has led to its being tried as a treatment for a wide range of sleep disorders, such as jet lag, primary insomnia, sleep-wake cycle disruption and sleep problems in children with neuro-developmental disorders.2<jats:sup>\u2013<\/jats:sup>6 Until recently, it had not been licensed in the UK for any indication. Prolonged-release melatonin (\u25bcCircadin \u2013 Lundbeck) has now been licensed as a treatment for primary insomnia. Here we consider whether this product has a place in the management of people with this condition.<\/jats:p>","DOI":"10.1136\/dtb.2009.06.0024","type":"journal-article","created":{"date-parts":[[2009,6,30]],"date-time":"2009-06-30T17:37:57Z","timestamp":1246383477000},"page":"74-77","source":"Crossref","is-referenced-by-count":2,"title":["\u25bcMelatonin for primary insomnia?"],"prefix":"10.1136","volume":"47","member":"239","published-online":{"date-parts":[[2009,6,30]]},"reference":[{"key":"2025082800070468000_47.7.74.1","unstructured":"European Medicines Agency. Assessment report for Circadin [online]. Available: http:\/\/www.emea.europa.eu\/humandocs\/PDFs\/EPAR\/circadin\/H-695-en6.pdf [Accessed 19 June 2009] 2007."},{"key":"2025082800070468000_47.7.74.2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.38731.532766.F6"},{"key":"2025082800070468000_47.7.74.3","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.38731.532766.F6"},{"key":"2025082800070468000_47.7.74.4","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-1497.2005.0243.x"},{"key":"2025082800070468000_47.7.74.5","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1111\/j.1469-8749.2004.tb00998.x","article-title":"Systematic review of melatonin treatment in children with neurodevelopmental disabilities and sleep impairment.","volume":"46","author":"Phillips","year":"2004","journal-title":"Dev Med Child Neurol"},{"key":"2025082800070468000_47.7.74.6","doi-asserted-by":"publisher","DOI":"10.1017\/S001216220400132X"},{"key":"2025082800070468000_47.7.74.7","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001520"},{"key":"2025082800070468000_47.7.74.8","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1136\/dtb.2004.421289","article-title":"What's wrong with prescribing hypnotics?","volume":"42","year":"2004","journal-title":"DTB"},{"key":"2025082800070468000_47.7.74.9","unstructured":"National Institute for Clinical Excellence. Guidance on the use of zaleplon, zolpidem and zopiclone for the short-term management of insomnia. Technology appraisal guidance 77 [online] Available: http:\/\/www.nice.org.uk\/nicemedia\/pdf\/TA077fullguidance.pdf [Accessed.19 June 2009] 2004."},{"key":"2025082800070468000_47.7.74.10","unstructured":"Joint Formulary Committee. British National Formulary Edition 57. BMJ Group and RPS Publishing March 2009."},{"key":"2025082800070468000_47.7.74.11","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.38623.768588.47"},{"key":"2025082800070468000_47.7.74.12","unstructured":"American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders Fourth Edition, Text Revision. Washington DC: American Psychiatric Association 2000."},{"key":"2025082800070468000_47.7.74.13","unstructured":"World Health Organization. International Statistical Classification of Diseases and Related Health Problems, 10th Revision, Version for 2007 [online] Available: http:\/\/www.who.int\/classifications\/apps\/icd\/icd10online\/navi.htm [Accessed 19 June 2009] 2006."},{"key":"2025082800070468000_47.7.74.14","unstructured":"American Academy of Sleep Medicine. The International Classification of Sleep Disorders 2nd ed: Diagnostic and coding manual. Westchester, Illinois: American Academy of Sleep Medicine 2005."},{"key":"2025082800070468000_47.7.74.15","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1185\/135525706X121138","article-title":"Insomnia: recent developments in definition and treatment.","volume":"11","author":"Atalay","year":"2006","journal-title":"Primary Care and Community Psychiatry"},{"key":"2025082800070468000_47.7.74.16","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1136\/dtb.1998.36215","article-title":"Melatonin for jet lag?","volume":"36","year":"1998","journal-title":"DTB"},{"key":"2025082800070468000_47.7.74.17","doi-asserted-by":"publisher","DOI":"10.1136\/dtb.1998.36215"},{"key":"2025082800070468000_47.7.74.18","unstructured":"Circadin 2mg prolonged-release tablets Summary of product characteristics, EU. Lundbeck Limited, 29\/07\/2008."},{"key":"2025082800070468000_47.7.74.19","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1111\/j.1365-2869.2007.00613.x","article-title":"Prolonged-release melatonin improves sleep quality and morning alertness in insomnia patients aged 55 years and older and has no withdrawal effects.","volume":"16","author":"Lemoine","year":"2007","journal-title":"J Sleep Res"},{"key":"2025082800070468000_47.7.74.20","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2869.2007.00613.x"},{"key":"2025082800070468000_47.7.74.21","unstructured":"The NHS Information Centre. Prescription Cost Analysis: England 2008 [online] Available: http:\/\/www.ic.nhs.uk\/webfiles\/publications\/PCA%202008\/PCA%202008v2.pdf [Accessed 19 June 2009]."},{"key":"2025082800070468000_47.7.74.22","unstructured":"Medicines and Healthcare products Regulatory Agency. Drug procurement advice. Restrictions on the import of unlicensed Melatonin products following the grant of a marketing authorisation for Circadin\u00c2\u00ae 2 mg tablets [online] Available: http:\/\/www.mhra.gov.uk\/NewsCentre\/CON023251 [Accessed 19 June 2009] 2008."},{"key":"2025082800070468000_47.7.74.23","first-page":"705","article-title":"Imported unlicensed medicines: requirements and current examples.","volume":"281","author":"Matthews","year":"2008","journal-title":"Pharm J"}],"container-title":["Drug and Therapeutics Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/dtb.2009.06.0024","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T07:07:17Z","timestamp":1756364837000},"score":1,"resource":{"primary":{"URL":"https:\/\/dtb.bmj.com\/lookup\/doi\/10.1136\/dtb.2009.06.0024"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,6,30]]},"references-count":23,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2009,6,30]]},"published-print":{"date-parts":[[2009,7]]}},"alternative-id":["10.1136\/dtb.2009.06.0024"],"URL":"https:\/\/doi.org\/10.1136\/dtb.2009.06.0024","relation":{},"ISSN":["0012-6543","1755-5248"],"issn-type":[{"type":"print","value":"0012-6543"},{"type":"electronic","value":"1755-5248"}],"subject":[],"published":{"date-parts":[[2009,6,30]]}}}